TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities March 11, 2022
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies January 24, 2022
TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition December 16, 2021
TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cell Therapies December 3, 2021
TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress November 11, 2021
